Regenerative medicine company MiMedx Group announced that it has added to its executive team, with Christopher Cashman becoming the company's executive vice president and chief commercialization officer.
In his new role, Cashman will contribute his expertise to the company's sales and marketing functions, strategic planning, and all related revenue growth initiatives. Most recently, Cashman was president and CEO of Sanuwave Health, a regenerative medicine company focused on the development and commercialization of extracorporeal shock wave technology for chronic wound care, orthopedic, cardiovascular, and plastic surgery.
MiMedx has supplied more than 300,000 allografts to date for application in the dental, wound care, surgical, sports medicine, and ophthalmic sectors of healthcare, according to the company.
